1. U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Clinical trial considerations to support Accelerated Approval of oncology therapeutics: guidance for industry. fda.gov, https://www.fda.gov/media/166431/download (2023).
2. Jones, C. The Best of 2022: FDA approvals and the breakthroughs that enabled them. Cancer research catalyst. aacr.org, https://www.aacr.org/blog/2022/12/30/the-best-of-2022-fda-approvals-and-the-breakthroughs-that-enabled-them/ (2022).
3. US Food and Drug Administration. Withdrawn | Cancer Accelerated Approvals. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals (2023).
4. Parikh, R. B. et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration Accelerated Approval. JAMA Oncol. 9, 567–569 (2023).
5. Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).